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Abstract
A substantial genetic contribution to systemic lupus erythematosus (SLE) risk is conferred by major histocompatibility
complex (MHC) gene(s) on chromosome 6p21. Previous studies in SLE have lacked statistical power and genetic resolution
to fully define MHC influences. We characterized 1,610 Caucasian SLE cases and 1,470 parents for 1,974 MHC SNPs, the
highly polymorphic HLA-DRB1 locus, and a panel of ancestry informative markers. Single-marker analyses revealed strong
signals for SNPs within several MHC regions, as well as with HLA-DRB1 (global p = 9.99610216). The most strongly associated
DRB1 alleles were: *0301 (odds ratio, OR = 2.21, p = 2.53610212), *1401 (OR = 0.50, p = 0.0002), and *1501 (OR = 1.39,
p = 0.0032). The MHC region SNP demonstrating the strongest evidence of association with SLE was rs3117103, with
OR= 2.44 and p= 2.80610213. Conditional haplotype and stepwise logistic regression analyses identified strong evidence
for association between SLE and the extended class I, class I, class III, class II, and the extended class II MHC regions.
Sequential removal of SLE–associated DRB1 haplotypes revealed independent effects due to variation within OR2H2
(extended class I, rs362521, p = 0.006), CREBL1 (class III, rs8283, p = 0.01), and DQB2 (class II, rs7769979, p = 0.003, and
rs10947345, p = 0.0004). Further, conditional haplotype analyses demonstrated that variation within MICB (class I, rs3828903,
p = 0.006) also contributes to SLE risk independent of HLA-DRB1*0301. Our results for the first time delineate with high
resolution several MHC regions with independent contributions to SLE risk. We provide a list of candidate variants based on
biologic and functional considerations that may be causally related to SLE risk and warrant further investigation.
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Introduction
Systemic lupus erythematosus (SLE) is the prototypic systemic
autoimmune disease characterized by autoantibody production
and involvement of multiple organ systems. Although the etiology
of SLE remains unknown, several lines of evidence underscore the
importance of genetic factors, including a high sibling risk ratio
(ls = 8–29), familial clustering, where approximately 10 to 12% of
SLE patients have an affected first-degree relative, and higher
concordance rates in monozygotic twins (24–69%) relative to
dizygotic twins and non-twin siblings (2–9%) [1,2,3].
Similar to many other autoimmune diseases, genes within the
major histocompatibility complex (MHC) on the short arm of
chromosome 6p21.3 exhibit strong association with the risk for SLE.
The MHC is a gene-dense region of the human genome
spanning approximately 4.5 Mb and known to encode more than
180 expressed genes [4,5]. Forty percent of the expressed loci have
functions related to immune activation and response. The class III
region, with more than 55 expressed loci, is the most dense
subregion of the MHC and the entire human genome [6].
Historically, interest in the MHC region for SLE has focused on
the highly polymorphic HLA class I and II genes that encode
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membrane glycoproteins that present peptides for recognition by
T lymphocytes, as well as genes within the HLA class III region,
particularly the tumor necrosis factor and complement component
C4 gene loci. Indeed, inherited deficiency of complement genes,
particularly C4A (null) alleles, has long been recognized as strong,
albeit rare, genetic risk factors for SLE [7]. Work by Graham and
colleagues [8,9] examining ,50 microsatellite markers across the
MHC region highlighted the importance of HLA class II
haplotypes involving the HLA-DRB1 and –DQB1 loci, particularly
those corresponding to serologic types HLA-DR2 and DR3
(DRB1*1501-DQB1*0602 and DRB1*0301-DQB1*0201, respec-
tively). More recently, genome wide association scans in SLE also
underscore the importance of the MHC [10,11,12]. However,
strong linkage disequilibrium (LD) between particular alleles
within the MHC has interfered with disease variant identification
and previous studies have not been able to distinguish between
associated MHC variants. Long-range, extended or ‘ancestral’
haplotypes, sometimes spanning greater than 2 Mb, have been
observed [8,13]. Recent studies in European-derived populations
have examined the distribution of LD across the MHC and have
suggested that SNPs can help dissect causal variation within this
region [14,15].
A recent analysis of 314 UK SLE families examining 68 SNPs
across the HLA class II and III regions and HLA-DRB1 suggested
two distinct association signals centered on DRB1*0301 and the T
allele of rs419788 in intron 6 of the class III region gene SKIV2L
[16]. Of interest, the class III signal appears to exclude the TNF -
308 promoter polymorphism, which has been a focus of prior work
[17]. Herein we extend this work by characterizing a much larger
collection of SLE cases (and parents) for 1,974 MHC genetic
markers plus the HLA-DRB1 locus. We also characterized SLE
cases for a set of ancestry informative markers (AIMs) to identify
population outliers and assess the possible impact of substructure
within the European population on our genetic association results.
Further, we utilized several analytic strategies to determine
whether multiple distinct alleles or haplotypes contribute to SLE
risk.
Results/Discussion
Table 1 summarizes characteristics of the 1,610 Caucasian SLE
cases and available parents (n = 1,470) from the complete trio
families included in this study. Clinical characteristics of the SLE
cases are consistent with those reported for Caucasian patients,
generally [18].
Table 2 summarizes association results for HLA-DRB1 alleles
in SLE cases and non-transmitted control alleles from parents of
the trio families [19]. Due to the highly polymorphic nature of
this locus and prior evidence suggesting that multiple HLA-DRB1
alleles influence SLE risk, we employed a relative predisposi-
tional effects (RPE) analysis [20] (see Methods). Results indicated
that three specific HLA-DRB1 alleles were strongly associated
with SLE risk: DRB1*0301 (odds ratio, OR= 2.21,
p = 2.53610212), *1401 (OR= 0.50, p = 0.0002) and *1501
(OR= 1.39, p = 0.0032). The DRB1*0801 allele, which has been
shown in previous work to be associated with SLE risk [8] was not
significantly associated with SLE in the current RPE analysis,
after accounting for testing of multiple DRB1 alleles (full results
shown in Table S1).
Figure 1 displays single marker association results for the 1,974
MHC SNPs (out of 2,360) passing quality control filters (see
Methods) in SLE cases compared to controls (additional results are
shown in Table S2). We observed strong association signals across
a broad region encompassing the HLA class I, III and II regions,
with weaker evidence of association in the extended class I and II
regions. The strongest evidence of association was observed at the
multiallelic DRB1 locus (global p = 9.99610216 and ORs as shown
in Table 2). The MHC region SNP demonstrating the strongest
evidence of association with SLE was rs3117103 (bp 32,457,535),
with OR=2.44 and p= 2.80610213. This SNP is flanking
C6orf10 at a distance of 9.8 kb.
Given the extensive LD across this region, we utilized
conditional analyses to identify association signals that were not
due to rs3117103. Similarly, we repeated these analyses condi-
tioning instead on the HLA-DRB1 locus, including the
DRB1*0301, *1401 and *1501 alleles. The rs number and map
position for all SNPs associated with SLE using the conditional
haplotype method (CHM) (total = 171 SNPs with p,0.01) are
Author Summary
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by autoantibody production and
involvement of multiple organ systems. Although the
cause of SLE remains unknown, several lines of evidence
underscore the importance of genetic factors. As is true for
most autoimmune diseases, a substantial genetic contri-
bution to disease risk is conferred by major histocompat-
ibility complex (MHC) gene(s) on chromosome 6. This
region of the genome contains a large number of genes
that participate in the immune response. However, the full
contribution of this genomic region to SLE risk has not yet
been defined. In the current study we characterize a large
number of SLE patients and family members for approx-
imately 2,000 MHC region variants to identify the specific
genes that influence disease risk. Our results, for the first
time, implicate four different MHC regions in SLE risk. We
provide a list of candidate variants based on biologic and
functional considerations that may be causally related to
SLE risk and warrant further investigation.
Table 1. Demographic and clinical characteristics of study
subjects.
Case Series (# SLE cases)* # trio families (# parents)
UCSF (925) 325 (650)
OMRF (429) 170 (340)
UMN (256) 240 (480)
Total # SLE cases: 1,610 Total # parents: 1,470
Female, % 92
Age at SLE diagnosis, mean (standard deviation) 33.1 (13.2)
History of renal involvement{, % 32
dsDNA autoantibody production{, % 54
Ethnicity (based on ancestry informative marker
data)
1,577 of 1,610 successful
$80% European ancestry 1,518 (96.3%)
$90% European ancestry 1,392 (88.3%)
$90% Northern European ancestry (estimated
for those with $90% European ancestry)
1,130 (71.1%)
* UCSF =University of California, San Francisco; OMRF =Oklahoma Medical
Research Foundation, UMN=University of Minnesota.
{renal involvement based on presence of American College of Rheumatology
renal criterion [35] and/or renal biopsy findings consistent with lupus nephritis.
{dsDNA=double strand DNA.
doi:10.1371/journal.pgen.1000696.t001
Multiple Regions within the MHC Influence SLE Risk
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provided in Table S3. Following these conditional analyses, several
analytic approaches were utilized to further define genetic variants
with the most compelling evidence of association with SLE risk, as
shown in Figure 2.
Figure 3 displays initial association results for the MHC region
variants (n = 11, including HLA-DRB1) that were shown to be
associated with SLE risk based on conditional haplotype and
stepwise logistic regression analyses, with p,0.001 (See Figure 2
and Methods). In addition to the HLA-DRB1 locus, there were
several variants with evidence of association with SLE, including
one variant in the extended class II region, five variants in HLA
class II (including HLA-DRB1), one variant in HLA class III, two in
HLA class I, and two in the extended class I region.
Figure 4 shows an LD plot representing the correlation (r2)
among HLA-DRB1 and the aforementioned 10 associated SNPs
that met our significance threshold of p,0.001 based on
conditional analyses (see Methods and Table S4). There was very
little evidence of LD among these 10 SNPs and HLA-DRB1 with
the exception of SNPs within the MICB (r2 = 0.58), C6orf10
(r2 = 0.53) and HLA-DQB2 loci (r2 = 0.35) and strong LD between
HLA-DRB1 and the C6orf10 locus (r2 = 0.77).
To further evaluate the evidence supporting association of these
10 variants with SLE we performed transmission disequilibrium
testing [21,22] among 650 complete trio families. These analyses
were consistent with the prior results, including strongest evidence
of association for rs3117103 (OR=2.44, p = 1.58610214). Addi-
tional details are shown in Table S5.
We also evaluated these 10 SNPs among a more homogeneous
subset of cases (and non-transmitted controls) estimated by AIMs
to have $90% Northern European ancestry. These results also
supported our main analyses, with the strongest evidence of
association for rs3117103 (OR= 2.49, p = 1.62610213) (see
Table S5 for additional details). Similarly, results for the top
four DRB1 risk alleles did not change when analyses were
Table 2. Association of HLA-DRB1 alleles with SLE risk based on relative predispositional effects (RPE) analysis of 1,522 SLE cases
and 693 controls.
HLA-DRB1 allele Case allele frequency Control allele frequency P-value{ Odds Ratio (95% C.I.){
*0301 0.206 0.110 2.53610212 2.21 (1.82, 2.68)
*1401 0.015 0.035 0.0002 0.50 (0.33, 0.75)
*1501 0.165 0.141 0.0032 1.39 (1.15, 1.66)
*0801 0.031 0.023 0.0293 1.59 (1.05, 2.39)
{P-values based on RPE analysis and therefore account for the other associated DRB1 alleles (see Methods).
{Reference group for odds ratio calculations included all DRB1 alleles except *0301, *0801, *1401, and *1501.
doi:10.1371/journal.pgen.1000696.t002
Figure 1. Association of 544 MHC region SNPs (out of 1,974) and HLA-DRB1 with SLE. Shown are results for variants with p,0.01 among
1,484 SLE cases and 650 controls. UNPHASED v.3.0.10 was used for 1,974 SNPs and SAS v. 9.1.3 for HLA-DRB1 global p-value. Odds ratio shown for
HLA-DRB1 corresponds to *0301 allele.
doi:10.1371/journal.pgen.1000696.g001
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repeated among the Northern European subset of cases and
controls (data not shown).
A distinguishing feature of the MHC region is the extensive,
long-range LD, which has been observed particularly among
European-derived populations [15] and is haplotype specific [23].
Thus, to further assess the independence of the 11 variants
(including DRB1) and determine whether one or more extended
haplotypes are strongly associated with SLE risk, we estimated
haplotypes involving these variants and evaluated the evidence of
association with SLE (see Methods). When case and control
chromosomes were considered together, a total of 171 unique
haplotypes were observed. When MHC haplotypes were com-
pared between SLE cases and controls, evidence of association was
revealed for two common haplotypes. The haplotype with the
strongest evidence of association with SLE contains the
DRB1*0301 allele (15% transmitted vs. 6% non-transmitted
haplotypes, OR=2.63, p= 8.32610215), which represents
,70% of the DRB1*0301 haplotypes. The other associated
haplotype contains the *1501 allele (9% transmitted vs. 6% non-
transmitted haplotypes, OR=1.54, p = 0.0025) (data not shown).
Finally, we considered our data both a) excluding and b)
conditioning on haplotypes containing the SLE-associated DRB1
alleles. More specifically, we compared MHC SNP allele
frequencies among cases vs. controls after sequentially removing
haplotypes containing *0301, *1501, and then *1401 (see Table 3
and Table S6). After removing haplotypes containing these alleles,
we observed no evidence for independent association of rs3117103
with SLE (p.0.30; see Table 3 and Table S6). However, four
MHC region variants remained significantly associated with SLE,
including rs362521 (OR2H2, extended class I region; p = 0.0060),
rs8283 (CREBL1, class III; p = 0.011), rs7769979 and rs10947345
(DQB2, class II; p = 0.0030 and 0.0004, respectively). Of interest,
two HLA class II region SNPs at the DQB2 locus remained
associated with SLE even in the absence of DRB1 risk alleles. This
is also the first study to support a role in SLE for variants within
the extended MHC class I region, near OR2H2. Next, the CHM
was used to investigate associations with the top 10 MHC region
SNPs conditioned on haplotypes containing the SLE-associated
HLA-DRB1 alleles (see Table 4 and Table S6). When conditioning
on DRB1*0301 haplotypes, we observed significant association
with SLE (p= 0.0059) for a SNP at the MICB locus (HLA class I).
In contrast, conditioning on DRB1*1501 or DRB1*1401 revealed
no evidence for other MHC effects on SLE risk, however limited
power was present for conditional analyses involving DRB1*1401
given the infrequency of that allele in this dataset. Finally, logistic
regression analyses involving the aforementioned five SNPs and
HLA-DRB1 revealed evidence of independent association with
SLE for all variants (p-values = 0.003 to,1026) with the exception
of one of the DQB2 SNPs (rs7769979) (data not shown).
In summary, we have characterized a large set of SLE cases and
parents of European ancestry for the highly polymorphic HLA-
DRB1 locus and ,2,000 SNPs across 4.9 Mb of the MHC. We
have employed methods to ensure that our main results are not
due to confounding by population admixture or major substruc-
ture within the European population. Our results support the
existence of multiple, independent association signals across this
region as opposed to a single primary association signal (with other
effects explained by LD). Independent associations within
Figure 2. Summary of analytical plan. Summary of analytical plan for defining MHC region genetic variants with independent contributions to
SLE risk among 1,484 SLE cases and 650 controls.
doi:10.1371/journal.pgen.1000696.g002
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extended class I and both class II and III regions were present,
even after accounting for HLA-DRB1 effects. However, we cannot
exclude the possibility that multiple associated variants within
MHC haplotypes function together to influence SLE risk through
co-regulation or other mechanisms.
An important limitation of the current analysis is the lack of
comprehensive coverage in the MHC region. For example, the
MHC Panel Set of markers was not designed to directly assess rare
variants or multi-allelic markers, such as insertion-deletion or copy
number variants. In addition, we have not characterized these
families for other classical HLA genes (besides HLA-DRB1), and in
fact our results implicate a role for other HLA class II region
genes. Thus, we cannot determine which, if any, of the associated
variants we have identified represent underlying causal variants,
versus proxies for causal variants as a result of LD. In order to
begin to address this important question we identified SNPs and
other variants tagged by the independently associated SNPs and
summarized their known function, as well as what is known about
these variants themselves (see Table S7).
One of the novel loci highlighted in the current study is OR2H2,
within the extended class I region, which encodes olfactory
receptor family 2, subfamily H, number 2. The olfactory receptor
proteins are G-protein-coupled receptors that share structure with
many neurotransmitter and hormone receptors [24]. To our
knowledge, this gene has not been implicated in risk of SLE or
other human autoimmune diseases. Our top SNP in this region
tags three additional SNPs in a single locus, gamma-aminobutyric
acid (GABA) B receptor, 1 (GABBR1, see Table S7), which is also a
neurotransmitter receptor [25]. Of relevance to this finding, recent
chromosome 6 sequencing efforts have now fully characterized the
extended MHC in humans [26], spanning a total of 7.6 Mb and
comprised of five subregions that include the original ‘classical’
MHC [27]. Of the 421 loci in this region, a total of 252 (60%) are
classified as expressed genes. Although our study included 305
SNPs within the extended class I MHC and 247 within the
extended class II MHC, more work is needed to interrogate the
entire extended MHC region.
Our top SNP within the class III region was located in the 39
untranslated region of CREBL1, which encodes c-AMP responsive
element binding protein-like 1 [28]. Of interest, we did not identify
additional variants tagged by our top SNP in this region (see Table
S7). Unfortunately, our MHCmarker set did not include SNPs within
or near the C4 locus, which has been previously associated with SLE.
In particular, copy number variation at this locus has been strongly
implicated in SLE risk. However, the two markers flanking the C4
locus did not reveal evidence for association with SLE in the current
study (rs389512 and rs1009382, p.0.15). Given the density of genes
within the class III region and previous work suggesting a contribution
of class III variants to SLE risk, further study of this region is clearly
warranted, including direct assessment of C4 variation.
We also demonstrated association of SLE with a variant near
the 59 end of the MHC class I chain-related B (MICB) gene, which
encodes a heavily glycosylated protein that serves as a ligand for
the NKG2D type 2 receptor [29]. Binding of this ligand activates
the cytolytic response of natural killer cells. This finding is also of
interest given previous evidence of association of the closely related
MICA gene to SLE [30], although results have been contradictory
[31]. The MICB gene has not been previously implicated in SLE
risk. All other variants tagged by our top SNP in this region are
within or very near the MICB locus (see Table S7).
Figure 3. Summary of MHC region variants with evidence of independent association with SLE. Summary of MHC region variants (n = 11,
including HLA-DRB1) with evidence of independent association with SLE (p,0.001) based on conditional haplotype and stepwise logistic regression
analyses. Number in parentheses indicates number of SNPs at that locus. See Figure 2 for details of overall analytical strategy. P-values from original
univariate analyses are shown on the y-axis.
doi:10.1371/journal.pgen.1000696.g003
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Figure 4. Linkage disequilibrium (LD) plot for HLA-DRB1 and 10 MHC region SNPs. LD plot showing correlation (r2) for HLA-DRB1 and 10
MHC region SNPs demonstrating evidence of independent association with SLE. A total of 2,607 individuals with.90% European ancestry (maximum
unrelated subset of all cases and trios) were used for analysis. Similar results were obtained when only the SLE cases or SLE trio family founders were
used to generate the LD plots (data not shown). HLA-DRB1 was coded as a biallelic marker (DRB1*0301 vs. others) for analysis in Haploview based on
results obtained for LD analyses of this locus as a multilocus marker using UNPHASED (see Methods). See Table 3 for other gene names.
doi:10.1371/journal.pgen.1000696.g004
Table 3. Results from relative predispositional effects analyses of top MHC SNPs in SLE cases and controls.
All Haps{ DRB1*0301 removed DRB1*0301, *1501 removed DRB1*0301, *1501, *1401 removed
SNP Gene P-value OR P-value OR P-value OR P-value OR
rs1536215 TRIM27 0.0037 0.72 0.0806 0.81 0.0627 0.78 0.0684 0.78
rs362521 OR2H2 0.0021 0.62 0.0065 0.64 0.0081 0.61 0.0060 0.60
rs3828903 MICB 3.2061027 0.67 0.0024 0.78 0.0759 0.86 0.0965 0.86
rs2246626 MICB 3.4561024 0.77 0.2570 0.91 0.7664 1.04 0.6680 1.04
rs8283 CREBL1 7.6761027 0.63 0.0013 0.74 0.0117 0.78 0.0111 0.78
rs7746019 C6orf10 7.85610212 1.77 0.1075 1.20 0.0244 1.30 0.0224 1.31
rs3117103 C6orf10 2.42610216 2.35 0.3961 1.47 0.3701 1.52 0.3699 1.50
rs7769979 DQB2 5.64610214 0.58 1.9061026 0.69 0.0013 0.75 0.0030 0.76
rs10947345 DQB2 6.9661024 1.29 1.2161027 1.53 0.0002 1.42 0.0004 1.40
rs383711 HSD17B8 0.0024 0.65 0.0308 0.73 0.0949 0.77 0.1082 0.77
OR=odds ratio.
{Haplotypes assigned in SLE cases and all family members using PHASE v. 2.1.2. Non-transmitted haplotypes were used as control group. Haplotypes containing SLE-
associated HLA-DRB1 alleles were sequentially removed (see Methods).
doi:10.1371/journal.pgen.1000696.t003
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Lastly, two HLA class II region SNPs at the DQB2 locus
remained associated with SLE even in the absence of DRB1 risk
alleles, and these two SNPs tag variants of at least four additional
class II loci (see Table S7). However, our study lacked power to
detect additional rare DRB1 associations (beyond *0301, *1501
and *1401), thus it is possible that additional DRB1 effects explain,
at least in part, the DQB2 association observed in the current
study.
We also sought to determine how our results compare to those
reported by Fernando, et al., based on their analysis of 68 SNPs in
the HLA class II and III regions, plus HLA-DRB1, in 314 UK SLE
families [16]. Two distinct association signals centered on
DRB1*0301 and the T allele of rs419788 in intron 6 of the class
III region gene SKIV2L were observed. Five SNPs within this gene
were included in our marker panel, including their top SNP,
rs419788. Four of the five SNPs were associated with SLE with
p,0.01 in our single marker analyses, however, only two of these
SNPs (but not rs419788) met the significance threshold (p,0.01)
for our CHM analyses. Neither of these two SNPs were among the
group of ten SNPs selected for further study based on conditional
haplotype based analyses or stepwise logistic regression.
We have not examined other, non-European populations in this
study and this represents a very important focus for future work
given the increased burden of SLE among those groups. Further,
comparison of MHC association results across major ethnic
groups, where LD patterns are substantially different, or the
analysis of specific disease subtypes may improve our ability to
localize causal variants within this region.
Methods
Ethics statement
Written consent was obtained from all study participants and
ethical approval for this study was obtained from the University of
California, San Francisco Committee on Human Research.
Subjects
SLE trio families and cases were derived from three indepen-
dent case series, including the UCSF Lupus Genetics Project
collection, the Lupus Genetics Studies and Lupus Family Registry
and Repository (http://lupus.omrf.org/) at the Oklahoma Med-
ical Research Foundation (OMRF) and the University of
Minnesota SLE collection. SLE cases from trio families (n = 735)
were a subset of the total set of SLE cases (n = 1,610), as shown in
Table 1. Details of recruitment and enrollment procedures have
been reported previously [32,33,34]. All subjects were self-
reported Caucasian and all SLE cases met the American College
of Rheumatology classification criteria for SLE [35,36]. Non-
transmitted HLA-DRB1 and MHC SNP alleles (described below)
from SLE trio family parents were used as ‘controls’ for all
comparisons with SLE cases, as previously described [19].
DNA samples
DNA was extracted from whole blood using the Gentra
Puregene Whole Blood Kit. DNA was obtained from buccal cells
and extracted using the Gentra Puregene Mouse Tail Kit. A total
of 50 ng of buccal cell or 25 ng of blood DNA (when necessary)
was whole genome amplified (WGA) using the Sigma WGA2 Kit
prior to genotyping. WGA samples were column purified using the
Sigma Genelute PCR Clean-up Kit. DNA was also extracted from
DNA Genotek Oragene saliva sample collection kits according to
the manufacturer’s protocol. Of the total 3,080 individual DNA
samples used for genotyping in this study, 69% were derived from
whole blood, 25% from buccal cells, and 6% from saliva; 72% of
all samples (including both blood and buccal) were WGA prior to
genotyping.
Genotyping methods
HLA-DRB1. Genotyping for the classical HLA-DRB1 locus
was performed using a PCR-Sequence-Specific Oligonucleotide
Probe (SSOP) methodology [37], also known as ‘‘linear array’’
technology. Briefly, this technology employs biotin-labeled
amplification products, generated from the polymorphic exons of
the HLA genes, in a hybridization reaction with a series of
unlabelled oligonucleotides. These oligonucleotides, which
correspond to variable sequence motifs in the genes, are
immobilized onto a nylon backed membrane. Hybridization is
visualized colorimetrically, and signal intensity is automatically
quantitated with a flatbed scanner and in-house software.
Genotype calling was achieved using SCORE, HLA genotyping
software developed by Dr. Wolfgang Helmberg (www.ncbi.gov).
The DRB1 HiRes assay specifically amplifies only DRB1 alleles,
thus removing the confounding signals from other DRB loci that
Table 4. Results from conditional haplotype method analyses of top MHC SNPs in SLE cases and controls.
DRB1*0301 only DRB1*1501 only DRB1*1401 only
SNP Gene P-value OR P-value OR P-value OR
rs1536215 TRIM27 0.16 0.48 0.7701 0.91 1.000 0.89
rs362521 OR2H2 0.43 0.68 0.4213 0.72 NA NA
rs3828903 MICB 0.0059 0.46 0.1216 0.61 0.3422 0.47
rs2246626 MICB 0.0615 0.59 0.4478 0.80 0.3614 0.48
rs8283 CREBL1 0.0122 0.32 1.0000 1.02 0.2220 NA
rs7746019 C6orf10 0.0189 1.94 0.6853 2.05 0.7403 1.40
rs3117103 C6orf10 0.0189 1.94 1.0000 1.36 NA NA
rs7769979 DQB2 0.0544 0.54 0.2374 0.70 0.2451 0.30
rs10947345 DQB2 0.8908 1.06 0.2536 1.37 0.2451 3.35
rs383711 HSD17B8 0.2428 0.43 0.2013 0.59 0.5988 0.43
OR=odds ratio.
{Haplotypes assigned in SLE cases and all family members using PHASE v. 2.1.2. Non-transmitted haplotypes were used as control group.
doi:10.1371/journal.pgen.1000696.t004
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can be found in commercial assays. A total of 100–200 ng was
used, depending on DNA source.
MHC SNP genotyping. All DNA samples were genotyped
for MHC region SNPs using the Combined MHC genotyping
panel (2,360 SNPs) from Illumina. This panel spans 4.9 Mb across
the MHC region with ,2 kb/SNP spacing and utilizes the robust
Golden-Gate technology [38]. The Combined MHC Panel Set is
comprised of both the Exon-Centric and Mapping panels. The
Exon-Centric Panel consists of 1,228 SNPs which are located in or
near coding regions (within 10 kb of exons). The Mapping Panel
consists of 1,293 SNPs. Genotyping was performed in a 96-well
format utilizing the 1,536 Sentrix Array Matrix (62). A total of
250 ng to 1 ug was used for each Illumina assay, depending on
source of DNA.
Ancestry informative markers (AIMs). A total of 384 SNP
markers selected for both Continental and European ancestry
informativeness, including differentiation between Northern vs.
Southern European origin were genotyped for all SLE cases
[39,40] (see Table S4). Genotypes were derived using a custom
Illumina Golden Gate 384 SNP panel (,65% of SLE cases) or the
Illumina HumHap 550 BeadChip (,35% of cases). A total of 22
samples were genotyped on both platforms for comparison (see
QC methods below)
Quality control analysis for DNA samples and
genotypes. Stringent quality control criteria were applied to
all samples and genotype data (HLA-DRB1, MHC region SNPs,
and AIMs). Sample success rate for HLA-DRB1 was 97.9%.
Mendelian inconsistencies for DRB1 were identified in five SLE
trio families. These individuals (n = 15) were excluded from
further analyses. A per-sample genotype rate threshold of 80%
was used for MHC SNP genotyping (total n = 173 samples
removed); a per-SNP genotype rate threshold of 90% was used
(total n = 337 SNPs removed). Additional criteria including
assessment of SNP minor allele frequency (,0.01), Hardy-
Weinberg equilibrium (p,0.001), and both Mendelian (.0.01)
and gender inconsistencies identified six additional families
(n = 18 individuals) and 49 additional SNPs for exclusion from
analyses. Analysis of replicate SNPs (n = 146 SNPs occurring on
both Illumina Mapping and Exoncentric panels) demonstrated
very strong evidence for agreement; 99.7% of all genotypes for all
samples compared were the same. Replicate sample comparisons
within and across DNA genotyping plates, as well as between
different sample sources (blood vs. saliva or blood vs. buccal) also
demonstrated very strong evidence for agreement (data not
shown). A total of 2,873 samples (665 trios and 878 SLE cases
without parents) and 1,974 MHC SNPs passed our stringent
quality control criteria. The mean distance between MHC SNPs
was 2.08 kb (range: 0.005–71.05 kb). The total MHC SNP
coverage spanned 4,913.28 kb. Similar quality control criteria
were used for all AIMs genotype data. A total of 27 SNPs were
removed from analysis, leaving a final dataset comprised of
genotypes from 357 SNPs (Table S4). A total of 22 samples were
genotyped using both platforms for comparison demonstrating
very high agreement (data not shown). Five additional SLE cases
and three additional trio families were removed from further
analyses due to missing AIM data. Results of AIM genotyping
and analysis among all SLE cases who reported Caucasian
ancestry revealed 51 SLE cases with an estimated European
ancestral contribution ,80% and these individuals (plus their
parents, total n = 75) were excluded from further analysis. Two
datasets were created for analysis of HLA-DRB1 and MHC SNP
loci based on European ancestry: .80% European ancestry (650
trio families and 834 SLE cases; total n = 2,784 individuals);
.90% European ancestry (614 trio families and 765 SLE cases;
total n = 2,607 individuals). The first of these datasets (.80%
European ancestry) was used for initial univariate and
conditional haplotype analyses (see below). The second dataset
(.90% European ancestry) was used for subsequent analyses. A
third dataset comprised of an even more genetically
homogeneous subgroup of cases (n = 1,379) who were estimated
based on AIMs to have at least 90% Northern (vs. Southern)
European ancestry was also used to examine the final MHC SNP
variants identified in the study.
Analysis of HLA-DRB1. Global testing for heterogeneity at
the DRB1 locus was performed using SAS v. 9.1.3 (Cary, NC). A
method to reveal the relative predispositional effects (RPEs)
(predisposing, protective, or neutral) of the HLA-DRB1 alleles
was also used, as previously described [20,41]. When a disease is
associated with two or more alleles at a locus, the RPE method
identifies the associations sequentially according to their strength;
thus the problem that a strong association with one allele can
create misleading deviations in the frequencies of other alleles is
alleviated.
Univariate analysis of MHC variants. Univariate analysis
of MHC region SNPs was performed using the log likelihood ratio
test implemented in the UNPHASED program v.3.0.10 [42].
Transmission disequilibrium testing (TDT) [21] analyses of
individual markers were performed using the PLINK program
[22].
Conditional methods of analysis. The conditional
haplotype method (CHM) [43,44], was used to initially
distinguish primary from secondary MHC associations. The
CHM is a test for homogeneity of relative allele frequencies in
cases and controls (or transmitted and non-transmitted alleles in
families) at a test locus on haplotypes identical for alleles at
another locus. Specifically, the CHM tests the null hypothesis of
equality in the distribution of transmitted (T) and non-
transmitted (NT) marker haplotypes identical at one variant
but different at another closely linked variant. If there is
heterogeneity between the T and NT (case-control) groups in the
distribution of two marker haplotypes identical at a predisposing
marker (variant A) but different at a putative predisposing
marker at another site (variant B), then this is evidence that
variant A does not entirely explain disease predisposition and
that variant B itself, or another marker in LD with variant B, is
influencing the relative association of variant A, and therefore
disease risk. We performed initial analyses of all MHC SNPs in
the SLE cases and non-transmitted controls, conditioning on the
top SNP and each DRB1 susceptibility allele. SNPs associated
with SLE at p,0.01 based on initial univariate analyses were
included in these analyses (n = 544 SNPs; see Figure 2). All
haplotype counts were determined using UNPHASED v.3.0.10
[42]. In addition, the CHM was used for analysis of the 11 final
MHC variants. Here, full haplotypes including HLA-DRB1 were
assigned using PHASE v.2.1.1, as described below. The Fisher’s
exact test in SAS was used to calculate OR, 95% CI and p-values
for each analysis.
We also used the WHAP program [45] version 2.09 (http://
pngu.mgh.harvard.edu/,purcell/whap/) to further evaluate the
variants identified using the CHM to have some evidence of
independent association with SLE susceptibility (p,0.01; see
above and Figure 1). A per-block WHAP method was utilized.
More specifically, within each haplotype block, we performed a
conditional analysis starting with HLA-DRB1, which was modeled
as a multi-allelic marker with values DRB1*0301, DRB1*1401,
DRB1*1501, or other. Starting with DRB1, we tested each
candidate marker for an independent effect; in particular this
uses a likelihood-ratio test to determine the significance (condi-
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tional p-value) of the difference between an ‘‘alternate’’ model
with 2-locus haplotypes - composed of DRB1 plus each new
candidate - versus the initial 1-marker (DRB1 only) ‘‘null’’ model.
As long as the most significant locus out of the list of candidates
has conditional p,0.01, we add this best marker to the list of
independent markers (now DRB1 plus one SNP), and proceed to
test all remaining SNPs as part of 3-marker haplotypes - again
composed of the current list plus each new candidate marker -
compared to our 2-locus model; and so on with larger haplotypes
as appropriate. The algorithm completes when no remaining
candidate SNP has p,0.01 conditional on the current list of
significant markers. Haplotype block structure for WHAP analysis
was defined using solid spline (http://www.biostat.wustl.edu/
genetics/geneticssoft/manuals/haploview/haploview_doc.pdf).
The Tagger program [46] was used to select MHC SNPs
identified from CHM analyses (p,0.01 as described above) for
further analysis using stepwise logistic regression modeling, and
also for retrieving tagged SNPs from CEPH Hap Map data as
previously described (see below). Stepwise logistic regression
analyses were performed using STATA v.9.2 (College Station,
Texas). Forward stepwise was performed using thresholds of
p,0.01 to add a variable and p$0.0101 to remove a variable
from our model. For the stepwise logistic regression analyses,
MHC SNPs were coded for presence/absence of the minor allele.
HLA-DRB1 was coded according to genotype for SLE associated
alleles (0301, 1501, and 1401), with all other alleles as the
reference group. Logistic regression analysis including the final top
MHC SNPs and HLA-DRB1 was performed using a similar
approach.
Imputation of missing MHC SNP data. Missing genotypes
for cases and non-transmitted controls were inferred using
default parameters in BEAGLE v2.1.3 [47]. The entire dataset
served as the reference group. Briefly, four haplotype pairs were
sampled per individual for each iteration of the phasing
algorithm. Ten iterations of the phasing algorithm were
performed. The threshold scale and threshold shift, which are
used to control the number of haplotype clusters in the graphical
model for the phased data, were set to 4.0 and 0.2, respectively.
The maximum number of consecutive markers considered for
determining whether to merge haplotype clusters was 500. The
number of missing genotypes imputed in this study was small, at
1.47% of all study genotypes (across 1,974 SNPs and 2,784
individuals, or ,5.5 million genotypes). We used the resulting
phased data file, which gives the most likely genotypes for each
individual, as input for stepwise logistic regression analyses of
cases and controls described above.
Linkage disequilibrium analyses. Haploview (v.4.1) [48]
was used to define LD among the final group of MHC SNP
variants using all cases and founders from SLE families. Similarly,
for the multi-allelic HLA-DRB1 locus, all pairwise measures of LD
with MHC region SNPs were determined using UNPHASED (-
LD option) [42]. Due to the restriction of Haploview to analyze
and display measures of LD for biallelic markers, HLA-DRB1 was
recoded. We chose DRB1*0301 vs. other alleles for this analysis
based on results obtained for LD analyses of this locus as a
multilocus marker using UNPHASED.
Haplotype assignment and analysis. PHASE v.2.1.1 was
used to assign extended multilocus haplotypes in all SLE cases and
parents comprised of HLA-DRB1 and our top 10 MHC SNPs.
Default settings for number of iterations (n = 100), thinning
interval (n = 1) and burn-in (n = 100) were used. RPE analysis
and tests of heterogeneity to compare MHC SNP effects on HLA-
DRB1 haplotypes were performed using SAS. OR, 95% CI and p-
values are reported.
Identification of tagged variants. LD data calculated by
HapMap for the CEPH population were downloaded directly
from the HapMap Genome Browser (http://hapmap.org/
cgi-perl/gbrowse) for phase I and II SNPs (release #23a, NCBI
Build 36, June 2008) and phase III SNPs (draft release #1, Sept
2008). For each study SNP, LD was assessed for all SNPs within
500 kb flanking each side of the SNP. In addition, for two of our
study SNPs not present in NCBI Build 36, CEPH genotypes were
downloaded directly from HapMap and LD between each of these
SNPs and other SNPs within 500 kb in NCBI Build 35 was
assessed using the Tagger algorithm as implemented in Haploview
(v 4.1) by force including each SNP and force excluding all others.
For each release and method, SNPs typed in the CEPH were
considered tagged by our study SNPs if they showed r2$0.80.
SNPs shown to be tagged, but already typed and assessed in our
study were not included as tagged variants. For study SNPs not
typed in both phases, LD between these SNPs and SNPs typed
only in the alternate phase could not be assessed. For study SNPs
not included in NCBI Build 36, LD could only be assessed
between these and SNPs typed in phase I and phase II that were
also present in NCBI Build 35. Annotation for each study SNP
and tagged SNP including nearest gene, SNP function, and
heterozygosity was taken from the UCSC Genome Browser
(http://genome.ucsc.edu/).
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